2 Outperform Rated Small Caps with Recent Pull-backs

Elite Pharmaceuticals (ELTP) and TSS, Inc. (TSSI), two Zacks' Outperform-rated small-cap stocks, recently experienced pullbacks despite reporting robust quarterly results. ELTP's Q4 FY25 revenues surged 78.3% to $31.9 million, driven by strong penetration in the ADHD generic market, though a non-cash warrant charge and competitive concerns contributed to its stock decline. Concurrently, TSSI's Q2 sales soared 262% to $44 million, propelled by its AI infrastructure 'picks and shovels' business and a new facility, yet its stock retreated due to flat EPS stemming from elevated depreciation and interest expenses related to its expansion. The article suggests these pullbacks may be overreactions, presenting potential entry points for investors given the companies' underlying operational strength and growth trajectories.

Analysis

Elite Pharmaceuticals (ELTP) and TSS, Inc. (TSSI) represent a dislocation between strong operational performance and recent negative stock price action. ELTP reported a 78.3% year-over-year revenue increase to $31.9 million in Q4 fiscal 2025, with operating income rising to $11.2 million from $3.7 million, driven by its capture of substantial market share in the generic ADHD market (20% of Adderall IR and 16% of Adderall ER). The stock's pullback appears attributable to headline noise, including a non-cash $7.2 million warrant charge that impacted EPS, alongside investor concerns about pricing pressure from increased competition and strategic uncertainty regarding a potential sale. Despite these concerns, the company's core business is margin-accretive and expanding. Similarly, TSSI, an AI infrastructure play, saw parabolic sales growth of 262% to $44 million in Q2 and raised its full-year 2025 adjusted EBITDA growth guidance from at least 50% to at least 75%. Its stock declined nearly 30%, a move likely driven by flat year-over-year EPS of $0.06, which was an expected consequence of elevated depreciation and interest expenses from a major new facility investment designed to meet future demand. While TSSI faces significant customer concentration risk, it maintains a solid balance sheet with $36.8 million in cash and strong operating cash flow.

Key Decisions for Investors

• Investors should look past Elite Pharmaceuticals' non-cash warrant charge and focus on its fundamental performance, including significant market share gains in the growing generic ADHD space, while monitoring for signs of margin erosion from increased competition.
• The nearly 30% pullback in TSS, Inc. stock, driven by expected and temporary margin compression from a strategic capacity expansion, may represent a compelling entry point for those bullish on AI infrastructure, but the high degree of customer concentration remains a critical risk to consider.
• For both companies, the current valuation multiples, which are elevated compared to sub-industry medians but below their own five-year highs, suggest that while growth is priced in, further upside is possible if they continue to execute on their respective strategies.
• Given the stated investor anxieties around a potential rushed sale of ELTP, any news regarding progress on a Nasdaq uplisting instead could serve as a significant positive catalyst for the stock.